Anthera Pharmaceuticals (NASDAQ:ANTH) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Wednesday.
According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “
Separately, ValuEngine upgraded shares of Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, December 31st.
A number of hedge funds and other institutional investors have recently bought and sold shares of ANTH. Armistice Capital LLC purchased a new position in shares of Anthera Pharmaceuticals in the fourth quarter worth about $1,269,000. BVF Inc. IL increased its stake in shares of Anthera Pharmaceuticals by 20.9% in the fourth quarter. BVF Inc. IL now owns 1,216,403 shares of the biopharmaceutical company’s stock worth $2,007,000 after purchasing an additional 209,896 shares in the last quarter. Finally, Wedbush Securities Inc. increased its stake in shares of Anthera Pharmaceuticals by 75.8% in the third quarter. Wedbush Securities Inc. now owns 73,764 shares of the biopharmaceutical company’s stock worth $106,000 after purchasing an additional 31,800 shares in the last quarter. Institutional investors and hedge funds own 16.21% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Anthera Pharmaceuticals (ANTH) Rating Lowered to Hold at Zacks Investment Research” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/14/anthera-pharmaceuticals-anth-rating-lowered-to-hold-at-zacks-investment-research.html.
Anthera Pharmaceuticals Company Profile
Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anthera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.